Physician profile
Gary Cecchi
NPI 1861480857
$7,675.40
in general payments reported to CMS, 2019-2025
52 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,660 · 2020: $302 · 2021: $918 · 2022: $294 · 2023: $1,475 · 2024: $1,760 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,501.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $976.88 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $794.40 | 2019-2024 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $498.58 | 2019-2024 | Darzalex, Akeega, Erleada |
| Novartis Pharmaceuticals Corporation | $423.11 | 2019-2025 | |
| Pfizer INC. | $413.59 | 2019-2025 | |
| Daiichi Sankyo INC. | $343.76 | 2019-2024 | Injectafer |
| Abbvie INC. | $291.54 | 2019-2025 | Venclexta |
| Amgen INC. | $273.01 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| Regeneron Healthcare Solutions, INC. | $266.74 | 2023-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $207.91 | 2019-2024 | Keytruda, Welireg |
| Genentech USA, INC. | $195.91 | 2019-2024 | Polivy, Phesgo, Tecentriq |
| Stemline Therapeutics INC. | $195.72 | 2019-2023 | Orserdu |
| Octapharma USA, INC. | $194.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $187.91 | 2019-2024 | Ninlaro, Alunbrig |
| Genzyme Corporation | $174.81 | 2019-2024 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Cecchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.